PNOC-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors

Next Previous
Trial Profile

PNOC-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 26 Nov 2016

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Nov 2016 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 21 Nov 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top